Effect of oral N-acetylcysteine in COPD - A randomised controlled trial

JK Practitioner

Volumn 14, Issue 1, 2007, Pages 12-16

  Bachh, Arshad Altaf ^a   Shah, Naveed Nazir ^a   Bhargava, Rakesh ^a   Ahmed, Zuber ^a   Pandey, D K ^a   Dar, Khurshid A ^a   Haq, Inaamul ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

COPD; Exacerbation; FEF25 75; FEV1; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; PLACEBO;

ADD ON THERAPY; ADULT; ANAMNESIS; ARTICLE; CHI SQUARE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPIROMETRY; STATISTICAL ANALYSIS;

EID: 34548107307     PISSN: 09718834     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1256-76.
2. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1988; 53: 129-36.
3. Gerrits CMJM, Herings RMC, Leufkens HGM, Lammers JWJ. N-acetylcysteine reduces the risk of re-hospitalization among patients with chronic obstructive pulmonary disease Eur Respir J 2003; 21: 705-98.
4. Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662-71.
5. MacNee W. Oxidants/antioxidants and COPD. Chest 2000; 117: 5 Suppl. 1:303S-17S.
6. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-80.
7. Warren JS, Johnson KJ, Ward PA. Consequences of oxidant injury. In: Crystal RG, West JB, Weibel ER, Barnes PJ, eds. The Lung: Scientific Foundations. New York, NY, Raven Press Ltd., 1997; pp 2279-88.
8. Burge PS, Calverley PMA, Jones PW, Spencer P, Anderson JA, Maslen TK. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
9. Anthonisen NR, Connect JE, Kiley JP. Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA 1994; 272: 1497-505.
10. Tunek A. Possible mechanisms behind the anti-inflammatory effects of N-acetylcysteine: is metabolism essential? Eur Respir Rev 1992; 2: 7, 35-8.
11. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effects of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16: 253-62.
12. Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary diseases. Eur J Respir Dis 1983; 64: 405-15.
13. Multicentre Study Group. Long-term oral acetyl-cysteine in chronic bronchitis. A double blind controlled study. Eur J Respir Dis 1980; 61 Suppl 111: 93-108.
14. Rasmussen JB, Gleenow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988; 1: 351-5.
15. McGavin CR, the British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985; 40: 823-35.
16. Quanjer Ph. Standardized lung function testing Eur Respir J 1993; 6 Suppl 16: 5-40.
17. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-5.
18. Hirshman JV. Do bacteria cause exacerbations of COPD? Chest 2000; 118: 193-193.
19. Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenza to human oropharyngeal epithelial cells in vitro. Respiration 2000; 67: 552-8.
20. Modeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986; 50: 31-42.
21. Aylward M, Maddock J, Dewland P. Clinical evaluation of acetylcysteine in the treatment of patients with chronic obstructive bronchitis: a balanced double-blind trial with placebo control. Eur J Respir Dis 1980;61 Suppl. 111: 81-9.
22. Grandjean EM, Berthet P, Ruffman R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22: 209-21.
23. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001; 322: 1-6.
24. Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomized, control trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med 2004; 4:13 Decramer, Dekhuijzen PNR, Troosters T, van Herwaarden C, Rutten-van Molken M, van Schayck CPO et al and the Bronchus-trial Committee. The Bronchitis Randomize on NAC Cost-Utility Study (BRONCUS): hypothesis and design. Eur Rcspir. J 2001; 17:329-36.